Attenuated poliovirus

Details Attenuated poliovirus Attenuated poliovirus

2009-03-16

2011-11-29

Li, Bao (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C424S217100

Reexamination Certificate

active

08066983

ABSTRACT:
A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.

REFERENCES:
patent: 6464972 (2002-10-01), Gromeier
Berwin, B., Reed, R.C., Nicchitta, C.V. “Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96”. J Biol Chem (2001); vol. 276:24, pp. 21083-21088.
Cello, J., Paul, A.V., Wimmer, E. “Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template”. Science (2002); vol. 297: pp. 1016-1018.
Cello, J., Toyoda, H., DeJesus, N., Wimmer, E. “Growth phenotypes and biosafety profiles in poliovirus receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses”. J. Med. Virol. (2008) ;vol. 80: pp. 352-359.
Coffey, M.C., Strong, J.E., Forsyth, P.A., Lee, P.W. “Reovirus therapy of tumors with activated Ras pathway”. Science (1998); vol. 282: pp. 1332-1334.
DeJesus, N., Franco, D., Paul, A., Wimmer, E., Cello, J. “Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence”. J Virol (2005); vol. 79:22, pp. 14235-14243.
Gromeier, M., Alexander, L., Wimmer, E. “Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants”. Proc Nati Acad Sci U S A (1996); vol. 93: pp. 2370-2375.
Gromeier, M., Bossed, B., Arita, M., Nomoto, A., Wimmer, E. “Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence”. J Virol (1999); vol. 73:2, pp. 958-964.
Gromeier, M., Lachmann, S., Rosenfeld, M.R., Gutin, P.H., Wimmer, E. “Intergeneric poliovirus recombinants for the treatment of malignant glioma”. Proc Natl Acad Sci U S A (2000); vol. 97:12, pp. 6803-6808.
Katzenstein, H.M., Cohn, S.L. “Advances in the diagnosis and treatment of neuroblastoma”. Curr Opin Oncol (1998); vol. 10: pp. 43-51.
Kirn, D., Martuza, R.L., Zwiebel, J. “Replication-selective virotherapy for cancer: biological principles, risk management, and future directions”. Nat Med (2001); vol. 7:7, pp. 781-787.
Koike, S., Taya, C., Kurata, T., et al. “Transgenic mice susceptible to poliovirus”. Proc Natl Acad Sci U S A (1991); vol. 88: pp. 951-955.
Kushner, B.H., Cheung, N.K., Kramer, K., Heller, G., Jhanwar, S.C. “Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review”. J Clin Oncol (1998); vol. 16: pp. 3880-3889.
Matthay, K.K., Villablanca, J.G., Seeger, R.C., et al. “Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid”. Children's Cancer Group. N Engl J Med (1999); vol. 341:16, pp. 1165-1173.
Mohr, I. “To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control”. Oncogene (2005); vol. 24: pp. 7697-7709.
Mueller, S., Wimmer, E. “Recruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to a(v)h3 integrin-containing membrane microdomains”. J Biol Chem (2003); vol. 278:33, pp. 31251-31260.
Mueller, S., Wimmer, E., Cello, J. “Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event”. Virus Res (2005); vol. 111: pp. 175-193.
Nakamura, H., Kasuya, H., Mullen, J.T., et al. “Regulation of herpes simplex virus g(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5”. J Clin Invest (2002); vol. 109: pp. 871-882.
Nemunaitis, J., Ganly, I., Khuri, F., et al. “Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial”. Cancer Res (2000); vol. 60: pp. 6359-6366.
Obuchi, M., Fernandez, M., Barber, G.N. “Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity”. J Virol (2003); vol. 77:16, pp. 8843-8856.
Ochiai, H., Moore, S.A., Archer, G.E., et al. “Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus”. Clin Cancer Res (2004); vol. 10: pp. 4831-4838.
Ochiai, H., Campbell, S.A., Archer, G.E, et al. “Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus”. Clin Cancer Res (2006); vol. 12: pp. 1349-1354.
Parato, K.A., Senger, D., Forsyth, P.A., Bell, J.C. “Recent progress in the battle between oncolytic viruses and tumours”. Nat Rev Cancer (2005); vol. 5: pp. 965-976.
Paul, A.V. “Possible unifying mechanism of picornavirus genome replication. In: Semler BL, Wimmer E, editors. Molecular biology of picornaviruses”. Washington (DC): ASM Press; (2002). pp. 227-246.
Paul, A.V., Yin, J., Mugavero, J., et al. “A “slide-back” mechanism for the initiation of protein-primed RNA synthesis by the RNA polymerase of poliovirus”. J Biol Chem (2003); vol. 278: pp. 43951-43960.
Pincus, S.E., Diamond, D.C., Emini, E.A., Wimmer E. “Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C”. J Virol (1986); vol. 57: pp. 638-646.
Porosnicu, M., Mian, A., Barber, G.N. “The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene”. Cancer Res (2003); vol. 63:pp. 8366-8376.
Reed, L.J., Muench, H. “A simple method of estimating fifty per cent endpoint”. Am J Hyg (1938); vol. 27: pp. 493-497.
Rieder, E., Paul, A.V., Kim, D.W., van Boom, J.H., Wimmer, E. “Genetic and biochemical studies of poliovirus cis-acting replication element cre in relation to VPg uridylylation”. J Virol (2000); vol. 74: pp. 10371-10380.
Ring, C.J. “Cytolytic viruses as potential anti-cancer agents”. J Gen Virol (2002); vol. 83: pp. 491-502.
Shiroki, K., Ishii T., Aoki, T., Kobashi M., Ohka, S., Nomoto, A. “A new cis-acting element for RNA replication within the 5′ noncoding region of poliovirus type 1 RNA”. J Virol (1995); vol. 69: pp. 6825-6832.
Solecki, D., Schwarz, S., Wimmer, E., Lipp, M., Bernhardt, G. “The promoters for human and monkey poliovirus receptors. Requirements for basic and cell type-specific activity”. J Biol Chem (1997); vol. 272: pp. 5579-5586.
Thorne, S.H., Hermiston, T., Kim, D. “Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects”. Semin Oncol (2005); vol. 32: pp. 537-548.
Toyoda, H., Ido, M., Hayashi, T., et al. “Experimental treatment of human neuroblastoma using live-attenuated poliovirus”. Int J Oncol (2004); vol. 24: pp. 49-58.
Van Der Wert, S., Bradley, J., Wimmer, E., Studier, F.W., Dunn, J.J. “Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase”. Proc Natl Acad Sci U S A (1986); vol. 83: pp. 2330-2334.
Wahby, A.F. “Combined cell culture enzyme-linked immunosorbent assay for quantification of poliovirus neutralization-relevant antibodies”. Clin Diagn Lab Immunol (2000); vol. 7: pp. 915-919.
Weinstein, J.L., Katzenstein, H.M., Cohn, S.L. “Advances in the diagnosis and treatment of neuroblastoma”. Oncologist (2003); vol. 8

Affiliated with

Also associated with

Rating

Attenuated poliovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Attenuated poliovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated poliovirus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4277635